Samalin Investment Counsel LLC Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Samalin Investment Counsel LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 25,418 shares of the biopharmaceutical company’s stock after acquiring an additional 605 shares during the quarter. Samalin Investment Counsel LLC’s holdings in Pfizer were worth $674,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. M Holdings Securities Inc. purchased a new position in shares of Pfizer during the fourth quarter worth approximately $57,000. Guardian Partners Inc. purchased a new position in shares of Pfizer in the fourth quarter worth $3,456,000. KLP Kapitalforvaltning AS purchased a new position in shares of Pfizer in the fourth quarter worth $72,144,000. Umpqua Bank purchased a new position in shares of Pfizer in the fourth quarter worth $263,000. Finally, Hillsdale Investment Management Inc. increased its stake in shares of Pfizer by 762.4% in the fourth quarter. Hillsdale Investment Management Inc. now owns 46,095 shares of the biopharmaceutical company’s stock worth $1,223,000 after buying an additional 40,750 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is currently owned by company insiders.

Pfizer Stock Performance

Shares of PFE stock opened at $26.20 on Friday. The stock has a market cap of $148.61 billion, a PE ratio of 18.58, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company’s fifty day moving average price is $26.17 and its 200-day moving average price is $27.04. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.10 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PFE has been the topic of several analyst reports. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group decreased their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.